Allan Camaisa - 12 Dec 2025 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role
Director
Signature
/s/ Andrew Jackson, Attorney-in-fact
Issuer symbol
CLDI
Transactions as of
12 Dec 2025
Net transactions value
-$1,237
Form type
4
Filing time
16 Dec 2025, 19:37:06 UTC
Previous filing
18 Dec 2024

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Camaisa Allan Director C/O CALIDI BIOTHERAPEUTICS, INC., 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO, /s/ Andrew Jackson, Attorney-in-fact 16 Dec 2025 0001990674

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDI Common Stock Sale $1,237 -850 -1.1% $1.46 76,952 12 Dec 2025 AJC Capital, LLC F1, F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected for estate and tax planning purposes by AJC Capital, LLC ("AJC"). The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request of the SEC staff, the Issuer or a security holder of the Issuer.
F2 Includes (i) 6,394 shares of Common Stock directly held by Allan Camaisa, (ii) 19,860 shares of Common Stock held by AJC, and (iii) 50,698 shares of Common Stock held by Jamir Trust.
F3 Does not include, (i) 1,526 shares of Common Stock issuable upon exercise of vested options within sixty (60) days held by Mr. Camaisa, (ii) 3,915 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, and (iii) 22,887 shares of Common Stock issuable upon exercise of vested options within sixty (60) days held by AJC.
F4 Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa is deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust.
F5 All share and share related information gives retrospective effect to the 1-for-12 reverse stock split effective on August 4, 2025.